Medicines List

Description

TromBye contains the active ingredient cilostazol, which belongs to a group of medicines called phosphodiesterase type 3 inhibitors.
Its actions are several and include dilating some blood vessels and reducing the clotting activity (to stick together) of some blood cells, called platelets, in the blood vessels.
TromBye has been prescribed for “intermittent claudication”. It is a spasmodic pain in the legs when walking and is caused by insufficient blood supply to the legs.

Indications

TromBye has been shown to improve the maximum and painless walking distance in patients with intermittent claudication who are painless at rest and without evidence of peripheral tissue necrosis (stage II peripheral arterial disease according to Fontaine).
TromBye is intended for use as a second-line agent in patients in whom lifestyle changes (including smoking cessation and controlled exercise programs) and other appropriate interventions have not sufficiently improved the symptoms of intermittent claudication.

Subject to medical prescription.

Concentration and pharmaceutical form: 100 mg tablets

Description

Tamayra Plus contains three active substances called ramipril, amlodipine and hydrochlorothiazide.

Ramipril belongs to a group of medicines called ACE inhibitors (Angiotensin Converting Enzyme Inhibitors). It works by:
–       Decreasing your body’s production of substances that could raise your blood pressure;
–       Making your blood vessels relax and widen;
–       Making it easier for your heart to pump blood around your body.

Amlodipine belongs to a group of medicines called calcium antagonists. It works by:
–       Relaxing blood vessels, so that blood passes through them more easily.

Hydrochlorothiazide belongs to a group of medicines called “thiazide diuretics” or water tablets. It works by:
–       Increasing the amount of water (urine) you produce. This lowers your blood pressure.

Indications

Tamayra Plus is indicated for:

• the treatment of high blood pressure (hypertension) in adult patients, who are adequately controlled with the individual products given concurrently at the same doses level as in the combination, but as separate tablets.

Subject to medical prescription.

Concentration and pharmaceutical form: 5 mg/5 mg/12,5 mg, 5 mg/5 mg/25 mg, 10 mg/5 mg/25 mg mg hard capsules

Description

Fluidoro, which contains the active substance prasugrel, belongs to a group of medicines called platelet antiplatelet agents.
Fluidoro inhibits the accumulation of platelets and thus reduces the risk of blood clots.

Indications

Fluidoro co-administered with acetylsalicylic acid (ASA) has been shown to prevent atherothrombotic events in adult patients with acute coronary syndrome (eg unstable angina, non-ST-segment elevation myocardial infarction [UA/NSTEMI] or myocardial infarction) of ST [STEMI] undergoing primary or delayed percutaneous coronary intervention (PCI).

Subject to medical prescription.

Concentration and pharmaceutical form: 10 mg film-coated tablets

Description

Zornichka belongs to group of medicines called thiazide diuretics. Thiazide diuretics help the body excrete excess fluid by stimulating the kidneys to excrete more urine.

Indications

Zornichka is indicated for:
– treatment of arterial hypertension, essential or nephrogenic, or isolated systolic hypertension. Zornichka can be used alone or in combination with other antihypertensive drugs;
– treatment of mild to moderate stable, chronic heart failure (NYHA functional class II-III) with stagnation;
– welling of specific origin:
— ascites due to cirrhosis of the liver in stable patients under close supervision;
— edema due to nephrotic syndrome, acute glomerulonephritis and chronic renal failure (with creatinine clearance > 30ml/min);
— corticosteroid and estrogen therapy.
– nephrogenic insipidus diabetes (Diabetes Insipidus).

Subject to medical prescription.

Concentration and pharmaceutical form: 12.5 mg, 25 mg tablets